Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.52 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028990 | 1.00 | POLB (0.53) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL22352087 | 1.00 | POLB (0.53) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL22352200 | 1.00 | POLB (0.53) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL16221579 | 1.00 | POLB (0.53) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL16410913 | 1.00 | POLB (0.53) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL20225019 | 0.92 | P2RY1 (0.62) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL20959779 | 0.92 | P2RY1 (0.62) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL18837728 | 0.92 | P2RY1 (0.62) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL20225051 | 0.92 | P2RY1 (0.62) | POLBP2RY1P2RY2SRCSMN1; SMN2 | |
| SCHEMBL285262 | 0.92 | P2RY1 (0.62) | POLBP2RY1P2RY2SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | IONIS PHARMACEUTICALS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11667663-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220204973-A1 | Antisense Oligonucleotide for Targeting Progranulin | HOFFMANN LA ROCHE (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022097117-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2022-05-12 | — | — | WO | disclosed |
| US-20220111028-A1 | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20210353760-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2021-11-18 | — | — | US | disclosed |
| WO-2021178818-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-09-10 | — | — | WO | disclosed |
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018100558-A2 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | WO | disclosed |
| US-20180092937-A1 | CYCLIC DINUCLEOTIDE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| WO-2017053722-A1 | MODULATORS OF KRAS EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016168592-A2 | COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2015168635-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168618-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015153800-A2 | COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015100394-A1 | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | SCN2A, SCN1A, SCN1B | POLB 3256/4885P2RY1 2640/4885P2RY2 1316/4885 |
| US-20220111028-A1 | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | STING1, TLR9, TLR3 | POLB 3088/4885P2RY1 50/4885P2RY2 108/4885 |
| US-20210353760-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | POLB 857/4885P2RY1 61/4885P2RY2 89/4885 |
| US-11667663-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, DUT | POLB 40/4885P2RY1 904/4885P2RY2 1143/4885 |
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, NTPCR | POLB 40/4885P2RY1 762/4885P2RY2 985/4885 |
| US-20180092937-A1 | CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, CGAS, IRF3 | POLB 345/4885P2RY1 15/4885P2RY2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.